Showing 4121-4130 of 23238 results for "".
Advances in Osteoporosis Treatment: Exploring Drug and Non-Drug Interventions
https://reachmd.com/programs/frontlines-osteoporosis/advances-in-osteoporosis-treatment-exploring-drug-and-non-drug-interventions/32344/Treatment for osteoporosis spans a variety of drug and non-drug interventions, from proper nutrition and exercise to anabolic and antiresorptive agents. In addition to understanding the importance of these therapies, it's crucial to recognize the patient's individual risks and needs and personalizeAPOL1 and Chronic Kidney Disease: New Findings in African Populations
https://reachmd.com/programs/clinicians-roundtable/apol1-and-chronic-kidney-disease-new-findings-in-african-populations/27031/Hear how recent findings on APOL1 variants and chronic kidney disease in Africa could help inform early detection strategies.AI in Neurology: What Tools Are Emerging?
https://reachmd.com/programs/neurofrontiers/ai-in-neurology-what-tools-are-emerging/13727/With AI technologies on the rise, we’re taking a look at what this could mean for the field of neurology.What to Know About a State-of-the-Art Approach to GIST Treatment
https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/what-to-know-about-a-state-of-the-art-approach-to-gist-treatment/9949/Ronald DeMatteo, MD, of Penn Medicine talks about diagnosis, treatment and research for the rare Gastrointestinal Stromal Tumor (GIST).Pain and Physical Function Improve after Weight-Loss Surgery
https://reachmd.com/programs/the-jama-report/pain-and-physical-function-improve-after-weight-loss-surgery/8051/Among a group of patients with severe obesity who underwent bariatric surgery, a large percentage experienced improvement in pain.Selecting First-Line Therapy in Gastric Cancers: A Biomarker-Driven Approach
https://reachmd.com/programs/project-oncology/selecting-first-line-therapy-in-gastric-cancers-a-biomarker-driven-approach/35505/Testing for biomarkers like PD-L1, HER2, claudin 18.2, and FGFR2b is reshaping our approach to first-line therapy in advanced gastric and gastroesophageal junction cancers. Alongside biomarker profiling, we must also weigh practical considerations around efficacy, toxicity, and patient-specific factAdvances in Sports Cardiology: Updates from ACC 2026
https://reachmd.com/programs/heart-matters/advances-sports-cardiology-acc-2026/54808/The field of sports cardiology has experienced remarkable growth, with new guidelines, expanding programs, and increasing recognition of cardiovascular risk in athletes. Hear from Dr. Jeffrey Hsu as he shares current and emerging approaches to risk assessment, prevention, and management of caExploring Cadherin-6: A Key Driver of Inflammation in Rheumatoid Arthritis
https://reachmd.com/programs/living-rheum/exploring-cadherin-6-a-key-driver-of-inflammation-in-rheumatoid-arthritis/32794/Despite advances in biologics, many patients with rheumatoid arthritis still experience persistent inflammation. However, cadherin-6 has recently been identified as a potential treatment target. Hear from Dr. Gary Firestein as he explains the discovery, function, and therapeutic potential of cadheriExploring Alzheimer’s Disease Risk Loci: 75 & Counting
https://reachmd.com/programs/neurofrontiers/exploring-alzheimers-disease-risk-loci-75-counting/13930/Emerging insights into the genetic landscape of Alzheimer’s disease and related dementias.IBD & Intimacy: Managing an Under-Recognized Issue
https://reachmd.com/programs/crohns-colitis-foundation-perspectives/ibd-and-intimacy-managing-an-under-recognized-issue/10081/Dr. Robert Frankel and Dr. Neilanjan Nandi discuss how to approach sexual and intimacy issues for IBD patients.